These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 16434009

  • 1. [Magnetic resonance imaging evidence of the effectiveness of combination chelation therapy in iron overload cardiomyopathy].
    Martín M, Estornell J, Orero M, Pérez JL, Ridocci F, Martínez V.
    Rev Esp Cardiol; 2006 Jan; 59(1):75-7. PubMed ID: 16434009
    [Abstract] [Full Text] [Related]

  • 2. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.
    Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174
    [Abstract] [Full Text] [Related]

  • 3. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
    Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.
    Hemoglobin; 2008 Apr 10; 32(1-2):29-34. PubMed ID: 18274980
    [Abstract] [Full Text] [Related]

  • 4. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 Apr 10; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 5. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A, Michaelides Y, Kontos C, Kyriacou K, Kontoghiorghes GJ.
    Hemoglobin; 2008 Apr 10; 32(1-2):17-28. PubMed ID: 18274979
    [Abstract] [Full Text] [Related]

  • 6. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 10; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 7. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F.
    Eur J Haematol; 2001 Jul 10; 67(1):30-4. PubMed ID: 11553264
    [Abstract] [Full Text] [Related]

  • 8. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH, Chang JS, Tsai CH, Peng CT.
    Ann Hematol; 2004 Jul 10; 83(7):471-3. PubMed ID: 14658011
    [Abstract] [Full Text] [Related]

  • 9. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
    Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2008 Jul 10; 32(1-2):41-7. PubMed ID: 18274982
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation therapy for children with transfusion-dependent β-thalassemia: How young is too young?
    Forni GL, Kattamis A, Kuo KHM, Maggio A, Sheth S, Taher AT, Viprakasit V.
    Pediatr Blood Cancer; 2024 Aug 10; 71(8):e31035. PubMed ID: 38753107
    [Abstract] [Full Text] [Related]

  • 11. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C.
    Haematologica; 2003 Dec 10; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
    Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.
    Hemoglobin; 2009 Dec 10; 33(5):323-31. PubMed ID: 19814678
    [Abstract] [Full Text] [Related]

  • 16. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Dec 10; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan 10; 23(1):48-56. PubMed ID: 22943064
    [Abstract] [Full Text] [Related]

  • 19. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY, Li JP, Weng TF, Wu KH, Chao YH.
    Ann Hematol; 2020 Oct 10; 99(10):2289-2294. PubMed ID: 32737633
    [Abstract] [Full Text] [Related]

  • 20. Chelation therapy for iron overload.
    Barton JC.
    Curr Gastroenterol Rep; 2007 Mar 10; 9(1):74-82. PubMed ID: 17335681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.